← Back to Clinical Trials
Recruiting NCT07449195

NCT07449195 A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07449195
Status Recruiting
Phase
Sponsor Memorial Sloan Kettering Cancer Center
Condition Ocular Tumor
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2026-02-27
Primary Completion 2028-02-27

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Intalight Dream OCTHeidelberg Spectralis OCT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2026-02-27 with a primary completion date of 2028-02-27.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to compare two devices used for optical coherence tomography (OCT). OCT is a noninvasive imaging (scanning) method that uses reflected light to create pictures of the back of the eye, and doctors can use OCT to detect and monitor different types of cancer

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years. * At least 1 eye that has an intraocular or ocular surface tumor. * The presence of a natural crystalline lens or intraocular lens. * Pupils that can dilate up to at least 3 mm in the study eyes. * The absence of opaque natural crystalline lenses or the presence of any ocular disease that prevents the view of the retina for imaging. * Patients must be able to fixate on the imaging target. * Patients must be able to sit still for a period of time (approximately 2 minutes). Exclusion Criteria: * Does not meet ALL of the above conditions

Contact & Investigator

Central Contact

Jasmine Francis, MD

✉ francij1@mskcc.org

📞 212-639-7266

Principal Investigator

Jasmine Francis, MD

PRINCIPAL INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Frequently Asked Questions

Who can join the NCT07449195 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Ocular Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07449195 currently recruiting?

Yes, NCT07449195 is actively recruiting participants. Contact the research team at francij1@mskcc.org for enrollment information.

Where is the NCT07449195 trial being conducted?

This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.

Who is sponsoring the NCT07449195 clinical trial?

NCT07449195 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Jasmine Francis, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology